Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Hitting the potholes

It's too early to say the party's over, but the path to riches is beginning to show cracks in its pavement.

The BioCentury 100 suffered its second consecutive big weekly loss, dropping 18 percent last week to finish 25 percent below its all-time high of 4369.56 two weeks ago.

As detailed in BioCentury Extra, on Tuesday, the downdraft was charged by misplaced worries over the patentability of genes and genetic information. Investors fled genomics stocks after President Clinton and U.K. Prime Minister Tony Blair issued a statement that raw genomic data should be freely available, triggering a 12 percent daily drop in the BioCentury 100 on the day, along with a 4 percent hit to the NASDAQ Composite.

Worriers also could point

Read the full 1191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE